MedTrace Logo

A Real World Experience of Dapagliflozin in Type 2 Diabetes

NCT02966626 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 223

Last updated 2018-10-12

No results posted yet for this study

Summary

Type 2 diabetes mellitus (T2DM) is creating a health pandemic globally. Management of type 2 diabetes involves combination of lifestyle intervention and drug intervention, which includes sodium-glucose transporter 2 (SGLT-2) inhibitors, such as dapagliflozin. Dapagliflozin (Forxiga®) was approved by the Malaysian Drug Authority for the treatment of type 2 diabetes in 2014. This study will describe the characteristics of patients who are prescribed dapagliflozin by diabetologists/endocrinologists in a tertiary referral center and describe their glycaemic control, weight, and renal function at baseline and during use of dapagliflozin.

Conditions

  • Type2 Diabetes

Sponsors & Collaborators

  • University of Malaya

    lead OTHER

Principal Investigators

  • Lee Ling LIM, MRCP (UK) · University of Malaya, Malaysia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2017-09-30
Completion
2018-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02966626 on ClinicalTrials.gov